Cel-Sci Corporation

CEL-SCI Corp (www.cel-sci.com) is a clinical-stage biotechnology company. The Company is focused on activating the immune system to fight cancer and infectious diseases. The Company is engaged in research and developing the treatments for the cancer and other diseases by using the immune system. The Company’s lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is in a pivotal Phase 3 clinical trial. Its Multikine is an investigational immunotherapy under development for the potential treatment of certain head and neck cancers. The Company using its Ligand Epitope Antigen Presentation System (LEAPS) technology platform is investigating product candidates include CEL-2000 and CEL-4000. CEL-2000 and CEL-4000, vaccine product candidates under development for treatment of rheumatoid arthritis. It is also investigating LEAPS COVID-19 conjugates as a potential treatment of coronavirus (COVID-19) in hospitalized and at-high-risk patients at the University of Georgia’s (UGA) Center.

• Cel-Sci Corporation